Sfoglia per Autore
Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens.
2006-01-01 Bonora S; Gonzalez de Requena D; Calcagno A; Milia MG; D’Avolio A; Sciandra M; Garazzino S; Siccardi M; Sinicco A; Di Perri G.
Unexpected drug-drug interaction between tipranavir/ritonavir (TPV/RTV) and enfuvirtide (T20)
2006-01-01 Gonzalez de Requena D; Calcagno A; Bonora S; Ladetto L; D’Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G.
Cut-off values of ribavirin trough concentration for sustained virological response and for hematological toxicity in HCV/HIV-co-infected patients treated with RBV and Pegylated Interferon
2007-01-01 Aguilar Marucco D; Gonzalez de Requena D; Veronese L; Bonora S; Ibanez A; Baietto L; D'Avolio A; Sciandra M; Sinicco A; Di Perri G
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients.
2008-01-01 Bonora S; D'Avolio A; Tettoni C; Siccardi M; Gonzalez de Requena D; Baietto L; Cometto C; Sciandra M; Trentini L; Di Perri G.
Evaluation of 7 different resistence interpretation algoritms and their derived gentotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens
2009-01-01 D. Gonzalez de Requena; S. Bonora; A. Calcagno; A. D’Avolio; O. Viganò; L. Baietto; C. Cometto; V. Ghisetti; M. Siccardi; S. Rusconi; G. Di Perri
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks
2009-01-01 Gonzalez de Requena D; Bonora S; Cometto C; Magnani S; D'Avolio A; Milia M; Vigano' O; Di Garbo A; Calcagno A; Siccardi M; Baietto L; Sciandra M; Rusconi S; Di Perri G.
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY
2009-01-01 Calcagno A.; Bonora S.; Cometto C.; Fontana S.; Aguilar D.; D'Avolio A.; de Requena D. Gonzalez; Maiello A.; Sinicco A.; Di Perri G
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting
2010-01-01 Calcagno A; Bonora S; Gonzalez De Requena D; Nozza S; D’Avolio A; Siccardi M; Simiele M; Castagna S; Lazzarin A; Di Perri G
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers
2010-01-01 Bonora S; D’Avolio A; Simiele M; Calcagno A; Baietto L; Chiesa M; Siccardi M; Gonzalez De Requena D; Sciandra M; Di Perri G.
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters
2010-01-01 Calcagno A; Bonora S; Lucchini A; Maiello A; Dal Conte I; Gonzalez de Requena D; D’Avolio A; Siccardi M; Di Perri G
Pharmacokinetics of maraviroc administered at 150 mg QD in association with lopinavir/ritonavir as a part of a novel NRTI-sparing regimen in naïve patiens
2011-01-01 Bonora S; Nozza S; Gonzalez de Requena D; Galli A; D'Avolio A; Calcagno A; Simiele M; Della Torre L; Lazzarin A; Di Perri G
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.
2011-01-01 Bonora S; Gonzalez de Requena D; D'Avolio A; Calcagno A; Tettoni M; Siccardi M; Baietto L; Simiele M; Trentini L; Di Perri G
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens.
2011-01-01 Gonzalez de Requena D; Bonora S; Viganò O; Calcagno A; Cometto C; D'Avolio A; Baietto L; Ghisetti V; Magnani S; Ferramosca S; Vitiello P; Galli M; Rusconi S; Di Perri G.
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE
2011-01-01 Calcagno A.; Bonora S.; Simiele M.; Audagnotto S.; Siccardi M.; de Requena D. Gonzalez; Romito A.; Imperiale D.; D'Avolio A.; Di Perri G
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting
2012-01-01 Calcagno A; Gonzalez de Requena D; Simiele M; D’Avolio A; Tettoni MC; Salassa B; Orofino G; Libanore V; Di Perri G; Bonora S
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment.
2012-01-01 Dʼavolio A;Ciancio A;Siccardi M;Smedile A;Simiele M;Cusato J;Baietto L;Marucco DA;Cariti G;Calcagno A;Gonzalez de Requena D;Sciandra M;Troshina G;Caviglia GP;Bonora S;Rizzetto M;Di Perri G
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function.
2013-01-01 Calcagno A;Gonzalez de Requena D;Simiele M;D'Avolio A;Tettoni M;Salassa B;Orofino G;Bramato C;Libanore V;Motta I;Bigliano P;Orsucci E;Di Perri G;Bonora S
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens. | 2006 | Bonora S; Gonzalez de Requena D; Calcagno A; Milia MG; D’Avolio A; Sciandra M; Garazzino S; Siccardi M; Sinicco A; Di Perri G. | |
| Unexpected drug-drug interaction between tipranavir/ritonavir (TPV/RTV) and enfuvirtide (T20) | 2006 | Gonzalez de Requena D; Calcagno A; Bonora S; Ladetto L; D’Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G. | |
| Cut-off values of ribavirin trough concentration for sustained virological response and for hematological toxicity in HCV/HIV-co-infected patients treated with RBV and Pegylated Interferon | 2007 | Aguilar Marucco D; Gonzalez de Requena D; Veronese L; Bonora S; Ibanez A; Baietto L; D'Avolio A; Sciandra M; Sinicco A; Di Perri G | |
| A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. | 2008 | Bonora S; D'Avolio A; Tettoni C; Siccardi M; Gonzalez de Requena D; Baietto L; Cometto C; Sciandra M; Trentini L; Di Perri G. | |
| Evaluation of 7 different resistence interpretation algoritms and their derived gentotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens | 2009 | D. Gonzalez de Requena; S. Bonora; A. Calcagno; A. D’Avolio; O. Viganò; L. Baietto; C. Cometto; V. Ghisetti; M. Siccardi; S. Rusconi; G. Di Perri | |
| Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks | 2009 | Gonzalez de Requena D; Bonora S; Cometto C; Magnani S; D'Avolio A; Milia M; Vigano' O; Di Garbo A; Calcagno A; Siccardi M; Baietto L; Sciandra M; Rusconi S; Di Perri G. | |
| GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY | 2009 | Calcagno A.; Bonora S.; Cometto C.; Fontana S.; Aguilar D.; D'Avolio A.; de Requena D. Gonzalez; Maiello A.; Sinicco A.; Di Perri G | |
| Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting | 2010 | Calcagno A; Bonora S; Gonzalez De Requena D; Nozza S; D’Avolio A; Siccardi M; Simiele M; Castagna S; Lazzarin A; Di Perri G | |
| Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers | 2010 | Bonora S; D’Avolio A; Simiele M; Calcagno A; Baietto L; Chiesa M; Siccardi M; Gonzalez De Requena D; Sciandra M; Di Perri G. | |
| Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters | 2010 | Calcagno A; Bonora S; Lucchini A; Maiello A; Dal Conte I; Gonzalez de Requena D; D’Avolio A; Siccardi M; Di Perri G | |
| Pharmacokinetics of maraviroc administered at 150 mg QD in association with lopinavir/ritonavir as a part of a novel NRTI-sparing regimen in naïve patiens | 2011 | Bonora S; Nozza S; Gonzalez de Requena D; Galli A; D'Avolio A; Calcagno A; Simiele M; Della Torre L; Lazzarin A; Di Perri G | |
| Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. | 2011 | Bonora S; Gonzalez de Requena D; D'Avolio A; Calcagno A; Tettoni M; Siccardi M; Baietto L; Simiele M; Trentini L; Di Perri G | |
| Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. | 2011 | Gonzalez de Requena D; Bonora S; Viganò O; Calcagno A; Cometto C; D'Avolio A; Baietto L; Ghisetti V; Magnani S; Ferramosca S; Vitiello P; Galli M; Rusconi S; Di Perri G. | |
| TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE | 2011 | Calcagno A.; Bonora S.; Simiele M.; Audagnotto S.; Siccardi M.; de Requena D. Gonzalez; Romito A.; Imperiale D.; D'Avolio A.; Di Perri G | |
| Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting | 2012 | Calcagno A; Gonzalez de Requena D; Simiele M; D’Avolio A; Tettoni MC; Salassa B; Orofino G; Libanore V; Di Perri G; Bonora S | |
| Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. | 2012 | Dʼavolio A;Ciancio A;Siccardi M;Smedile A;Simiele M;Cusato J;Baietto L;Marucco DA;Cariti G;Calcagno A;Gonzalez de Requena D;Sciandra M;Troshina G;Caviglia GP;Bonora S;Rizzetto M;Di Perri G | |
| Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. | 2013 | Calcagno A;Gonzalez de Requena D;Simiele M;D'Avolio A;Tettoni M;Salassa B;Orofino G;Bramato C;Libanore V;Motta I;Bigliano P;Orsucci E;Di Perri G;Bonora S |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile